High-Throughput Platforms for Screening of Pharmaceutical Solids and Lipid Nanoparticles

eN-RAMPS LLC is advancing next-generation microfluidic platforms that accelerate the discovery, optimization, and manufacturing of complex materials and formulations. This talk will highlight two flagship systems: eN-LNP and eN-XTAL. The eN-LNP platform is a high-throughput, microfluidics-based system designed for the scalable and parallel synthesis of lipid nanoparticles (LNPs), a critical technology for RNA therapeutics and vaccines. Leveraging a physics-informed array of confined impinging jet (CIJ) micromixers, the system achieves sub-millisecond mixing of lipid and aqueous phases to generate LNPs with tight size control, low polydispersity, and high encapsulation efficiency. Its 96-well modular format enables dozens of distinct formulations in a single run, accelerating design-of-experiments strategies for formulation screening, while advanced 3D printing allows rapid prototyping of solvent-resistant, biocompatible microfluidics. In parallel, the eN-XTAL system, developed in collaboration with ETC, has achieved TRL 7 and is now being advanced toward full automation at TRL 8+. This platform integrates continuous-flow microfluidics with electrochemical, Raman, and optical sensors to measure supersaturation, polymorphism, turbidity, nucleation, and crystal growth rates. Coupled with a motorized xyz-stage and a user-friendly graphical interface, eN-XTAL enables rapid, reliable screening of crystallization pathways and process optimization. Together, these platforms exemplify eN-RAMPS’ mission to deliver modular, automated, and scalable solutions that bridge fundamental science and industrial deployment in pharmaceuticals, energy, and materials manufacturing.